Literature DB >> 33471710

Unilateral Tnm T1 And T2 Papillary Thyroid Carcinoma With Lateral Cervical Lymph Node Metastasis: Total Thyroidectomy or Lobectomy?

Zhihong Wang1, Jingzhe Xiang1, Zhiqiang Gui1, Yuan Qin1, Wei Sun1, Jiapeng Huang1, Liang He1, Wenwu Dong1, Dalin Zhang1, Ting Zhang1, Liang Shao1, Chengzhou Lv1, Ping Zhang1, Hao Zhang2.   

Abstract

OBJECTIVE: The aim of this study was to explore the effect of total thyroidectomy (TT) and lobectomy (LT) on the prognosis of unilateral papillary thyroid carcinoma (PTC) with lateral cervical lymph node metastasis.
METHODS: Patients with PTC and lateral cervical lymph node metastasis who underwent lateral cervical lymph node dissection between January 2007 and December 2016 were retrospectively reviewed. To investigate the effect of surgical procedure on the prognosis of lymph node metastasis patients, other high-risk factors such as extrathyroidal invasion and large tumor size were excluded. All patients were in Tumor-Node-Metastasis (TNM) stage T1 and T2. Primary end point was recurrence-free survival (RFS).
RESULTS: Among 264 PTC patients, 104 (39.4%) patients received TT and 160 (60.6%) patients received LT. With a median follow-up of 50 months (interquartile range, 34 to 74 months), 7 patients (2.65%) experienced recurrence. The 5-year RFS in the TT and LT groups was 96.1% and 97.7%, respectively, and was not significantly different (P = .765). Similar results were found when excluding patients who received radioiodine ablation, which were 97.7% and 97.4%, respectively (P = .752). Age ≥55 years (hazard ratio, 7.368; P = .018) and multifocality in the ispi-lateral lobe (hazard ratio, 10.059; P =.006) were identified as independent risk factors of recurrence.
CONCLUSION: For unilateral TNM T1 and T2 PTC patients with lateral lymph node metastasis, there was no significant difference in the effect of TT and LT for RFS in the absence of other risk factors during the follow-up period. Patient age ≥55 years with multifocality in the unilateral lobe might be independent risk factors for prognosis.
© 2020 American Association of Clinical Endocrinologists. Published by Elsevier, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33471710     DOI: 10.4158/EP-2020-0125

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  2 in total

1.  Therapeutic Strategy in Low-Risk Papillary Thyroid Carcinoma - Long-Term Results of the First Single-Center Prospective Non-Randomized Trial Between 2011 and 2015.

Authors:  Agnieszka Czarniecka; Marcin Zeman; Grzegorz Wozniak; Adam Maciejewski; Ewa Stobiecka; Ewa Chmielik; Malgorzata Oczko-Wojciechowska; Jolanta Krajewska; Daria Handkiewicz-Junak; Barbara Jarzab
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-06       Impact factor: 5.555

2.  Optimal Surgical Extent in Patients with Unilateral Multifocal Papillary Thyroid Carcinoma.

Authors:  Joohyun Woo; Hyungju Kwon
Journal:  Cancers (Basel)       Date:  2022-01-15       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.